Mostrando 10 resultados de: 19
Filtros aplicados
Publisher
Pharmacogenomics(4)
Pharmacogenomics Journal(3)
Drug Metabolism and Drug Interactions(2)
Drug Metabolism and Personalized Therapy(2)
Revista de Biologia Tropical(2)
Área temáticas
Farmacología y terapéutica(17)
Enfermedades(8)
Bioquímica(7)
Medicina y salud(5)
Fisiología humana(3)
Origen
google(3)
An update on HLA alleles associated with adverse drug reactions
ReviewAbstract: Adverse drug reactions (ADRs) are considered as an important cause of morbidity and mortality. The hPalabras claves:abacavir, adverse drug reactions, Allopurinol, carbamazepine, human leukocyte antigen (HLA), hypersensitivity syndrome, pharmacogenetics, Stevens-Johnson syndromeAutores:Adrián LLerena, Fricke-Galindo I., López-López M.Fuentes:scopusCYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy
ArticleAbstract: We aimed to explore the possible influence of CYP2C9 (∗2, ∗3 and IVS8-109 A>T), CYP2C19 (∗2, ∗3 andPalabras claves:Autores:Adrián LLerena, Dorado P., Familiar-López I., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas
ArticleAbstract: Aim: In previous CYP2D6 genotyping studies in Mexican-Amerindians a very low frequency of poor metabPalabras claves:CYP2D6, Lacandones, Mexican-Mestizo, pharmacogeneticsAutores:Adrián LLerena, Alonso E., Dorado P., López-López M., Ochoa-Morales A., Ortega A., Penãs-Lledó E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusCarbamazepine adverse drug reactions
ReviewAbstract: Introduction: Carbamazepine (CBZ) is used for the treatment of epilepsy and other neurological and pPalabras claves:adverse drug reactions, carbamazepine, Hepatotoxicity, Hypersensitivity, hyponatremia, Stevens-Johnson syndrome, Teratogenesis, toxic epidermal necrolysisAutores:Adrián LLerena, Fricke-Galindo I., Jung-Cook H., López-López M.Fuentes:scopusAllele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers
ArticleAbstract: Aim: To determine allele and genotype frequencies of genes influencing anti-epileptic drug therapy iPalabras claves:ABCC2, anti-epileptics, CYP3A5, EPHX1, GABRA1, HNF4A, Mexican-Mestizo, NR1I2, pharmacogenetics, RALBP1, SCN1A, SCN2A, UGT1A1, UGT2B7Autores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.Fuentes:scopusGenomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
ArticleAbstract: We present the distribution of CYP2D6, CYP2C9, and CYP2C19 variants and pbkp_redicted phenotypes inPalabras claves:Autores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Michelin L.A., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusErratum: CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients (Molecular Psychiatry (2013) 18 (266))
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Alonso E., Dorado P., Jung H., López-López M., Naranjo M.E.G., Ortega A., Penãs-Lledó E.M., Trejo H.D.Fuentes:scopusEvaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: The CEIBA cocktail
ReviewAbstract: Interindividual differences in response to drug treatments are mainly caused by differences in drugPalabras claves:Cocktail, Cytochrome P450 (CYP), Genotype, Hispanics, PhenotypeAutores:Adrián LLerena, Alonso-Vilatela E., Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Fiedler J., Francisco J.López Hernández, Galaviz-Hernandez C., Garza-Ocañas L., González-Vacarezza N., Grazina M., Herrera L., Jiménez-Arce G., Lares-Asseff I., Lazalde-Ramos B.P., Leonardo J. Beltrán, López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Natalia Heras, Ochoa-Morales A., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rojas-Martinez A., Rojas-Ponce R., Sarmiento A.P., Sosa-Macías M.G., Tarazona-Santos E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusEthnic background and CYP2D6 genetic polymorphisms in Costa Ricans
ArticleAbstract: CYP2D6 differences have already been demonstrated within Latin American populations by the CEIBA.FPPalabras claves:Afro-Caribbean, Amerindian, COSTA RICA, CYP2D6, MESTIZO, Poor metabolizers, populations, Ultrarapid metabolizersAutores:Adrián LLerena, Barrantes R., Calzadilla L.R., Céspedes-Garro C., Enrique Terán, Estévez-Carrizo F.E., Grazina M., Jiménez-Arce G., López-López M., María-Eugenia G.N., Moya G.E., Ortiz-López R., Ramírez-Roa R., Rodeiro I., Sarmiento A.P., Sosa-Macías M.G., Tarazona-Santos E.M.Fuentes:scopusInfluence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy
ArticleAbstract: Genetic and nongenetic factors may contribute to lamotrigine (LTG) plasma concentration variabilityPalabras claves:Autores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M., Rojas-Tomé I.S.Fuentes:scopus